Auxly Cannabis to acquire CRO KGK for $12.3M in cash, stock deal | Digital…
Auxly Cannabis Group reached an agreement to acquire KGK, a Canadian CRO focused on health and wellness, in a cash and stock deal worth $12.3 million. Auxly,…
Browsing Tag
science
Hesperos gains NIH funding for Alzheimer’s ‘human-on-a-chip’ trials |…
It’s a devastating memory-wasting disease that has continually seen failure after failure in the clinic, but now a Florida medtech company is hoping it can…
Sutro Biopharma eyes $75M IPO to push antibody-drug conjugates | Digital…
Sutro Biopharma is at it again—on the heels of an $85 million private round, the oncology player has filed to raise up to $75 million in its IPO. The funding…
Vertex taps Genomics for target discovery help, makes investment | Digital…
Vertex has joined with Genomics to use genetics and machine learning to improve target discovery. The partnership will leverage a platform that collates and…
FDA starts pilot to help sponsors use novel trial designs | Digital Science
The FDA has initiated a pilot program (PDF) to help drug developers use complex innovative trial designs (CID). Sponsors accepted into the four-year pilot will…
Researchers are turning to deadly venoms in their quests for life-saving…
Venomous reptiles, bugs and marine life have notorious reputations as dangerous, sometimes life-threatening creatures. But in a paper in the current issue of…
Bigger proteins, stronger threads: Synthetic spider silk | Digital Science
Spider silk is among the strongest and toughest materials in the natural world, as strong as some steel alloys with a toughness even greater than bulletproof…
What Happens When A Farmer Attends a Food Science Convention? | Digital…
The story could start with a farmer and a food scientist walk into a bar…or a restaurant…or a grocery store…or the Food Expo at IFT18: A Matter of Science and…
Another setback for AstraZeneca as lupus drug fails phase 3 test | Digital…
Despite encouraging midstage data for AstraZeneca’s drug for systemic lupus erythematosus (SLE), anifrolumab has missed the target in the first of two ongoing…
Sequoia leads $7M seed round for T-cell player RootPath | Digital Science
RootPath, the brainchild of scientists and bioengineers from MIT, Harvard, Stanford and the like, has raised $7 million in seed funding to develop a T-cell…